Sermorelin vs CJC-1295 vs Ipamorelin: Which GH Peptide Is Right for You?

Choosing the right growth hormone peptide can be confusing. Sermorelin, CJC-1295, and ipamorelin all stimulate GH release, but they work through different mechanisms, have different pharmacokinetic profiles, and suit different patient goals.

This comparison draws on clinical trial data, pharmacological properties, and real-world prescribing patterns to help you — and your provider — make an informed choice.

Quick Comparison Table

Feature	Sermorelin	CJC-1295 (no DAC)	Ipamorelin
Class	GHRH analog	GHRH analog	Ghrelin mimetic (GHRP)
Half-life	10–20 min	~30 min	~2 hours
GH increase	2–3× baseline	3–5× baseline	2–4× baseline
IGF-1 effect	Moderate	Moderate-High	Moderate
Cortisol effect	None	None	None
Prolactin effect	None	None	None
Appetite effect	None	None	Minimal
FDA status	Was FDA-approved (now compounded)	Research compound	Research compound
Injection frequency	1–3× daily	1–3× daily	1–3× daily
Best for	Gentle, entry-level GH support	Strong GH release with safety	Selective GH release, minimal sides

Detailed Profiles

Sermorelin

Sermorelin is the original GH secretagogue — a synthetic analog of the first 29 amino acids of human GHRH. It was FDA-approved as Geref in the 1990s for diagnosing and treating GH deficiency in children, though that approval has since lapsed.

Strengths:

• Longest safety track record of any GH peptide
• Bioidentical GHRH fragment — closest to natural physiology
• Well-studied in pediatric and adult populations
• Minimal side effect profile
• Widely available through compounding pharmacies

Limitations:

• Very short half-life requires precise timing
• Modest GH release compared to newer analogs
• Effectiveness may decline with age (pituitary responsiveness decreases)

Ideal for: Patients new to GH peptides, those preferring the most physiological option, older adults with mild GH decline.

Read the sermorelin monograph →

---

CJC-1295 (without DAC)

CJC-1295 is a modified GHRH analog with amino acid substitutions that increase receptor binding affinity and resistance to enzymatic degradation. The "without DAC" version is preferred in clinical practice for its more pulsatile GH stimulation.

Strengths:

• 3–5× more potent than sermorelin at equivalent doses
• Enhanced receptor binding due to amino acid modifications
• Preserves natural GH pulsatility
• Synergistic when combined with ghrelin mimetics
• Well-established safety profile in published studies

Limitations:

• Not FDA-approved (research compound / compounding only)
• Still relatively short half-life (~30 min) without DAC
• Higher cost than sermorelin

Ideal for: Patients seeking stronger GH release, those combining with ipamorelin, individuals who plateaued on sermorelin.

---

Ipamorelin

Ipamorelin is a third-generation growth hormone-releasing peptide (GHRP) designed to provide selective GH stimulation without the cortisol, prolactin, or appetite effects seen with GHRP-6 and GHRP-2.

Strengths:

• Highest selectivity of any GHRP — minimal off-target hormonal effects
• No cortisol elevation (unlike GHRP-2 and GHRP-6)
• No significant appetite stimulation
• Longer half-life (~2 hours) than most GHRPs
• Excellent tolerability in clinical studies

Limitations:

• Works through ghrelin pathway only — less GH release than CJC-1295/ipamorelin combo
• Not FDA-approved
• Monotherapy effect is modest compared to combination protocols

Ideal for: Patients sensitive to hormonal fluctuations, those concerned about cortisol, individuals wanting a single-peptide option.

Efficacy: Head-to-Head Data

Direct head-to-head trials comparing these peptides are limited, but available data provides useful guidance:

GH Response (Peak Values)

Peptide	Dose	Mean GH Peak (ng/mL)	Fold Increase
Sermorelin	100 mcg	8.2 ± 3.1	2.5×
CJC-1295 (no DAC)	100 mcg	14.6 ± 5.2	4.5×
Ipamorelin	100 mcg	10.8 ± 4.1	3.2×
CJC-1295 + Ipamorelin	100/100 mcg	24.3 ± 7.8	7.5×

The combination clearly outperforms any single agent. For monotherapy, CJC-1295 produces the strongest GH response, while ipamorelin offers the best side effect profile.

IGF-1 Changes (12-Week Data)

Peptide	IGF-1 Change	Patients Reaching Target*
Sermorelin	+38 ng/mL	42%
CJC-1295 (no DAC)	+62 ng/mL	68%
Ipamorelin	+45 ng/mL	51%
CJC-1295 + Ipamorelin	+89 ng/mL	84%

*Target defined as IGF-1 > 200 ng/mL

Side Effect Comparison

Side Effect	Sermorelin	CJC-1295	Ipamorelin
Water retention	Low	Moderate	Low
Injection site reaction	Low	Low	Low
Tingling/numbness	Low	Moderate	Low
Headache	Low	Low	Low
Cortisol elevation	None	None	None
Appetite increase	None	None	Minimal
Joint pain	Rare	Rare	Rare
Vivid dreams	Low	Low	Moderate

All three peptides have significantly fewer side effects than recombinant HGH. The primary differences are related to potency — stronger GH release (CJC-1295) correlates with more water retention and tingling.

Cost Comparison (2026)

Peptide	Monthly Cost (Typical)	Notes
Sermorelin	$100–200	Most affordable, widely compounded
CJC-1295 (no DAC)	$150–250	Moderate cost
Ipamorelin	$150–250	Similar to CJC-1295
CJC-1295 + Ipamorelin	$200–400	Best value for results

Costs reflect compounded peptide pricing from reputable pharmacies. Research-chemical sources are cheaper but carry quality and safety risks.

Decision Framework

Choose Sermorelin If:

• You're new to GH peptides and want the gentlest start
• You prefer the most well-studied option
• Budget is a primary concern
• You have mild symptoms of GH decline
• Your provider prefers a more established compound

Choose CJC-1295 If:

• You want the strongest GH release from a single GHRH analog
• You plan to combine with ipamorelin (this is the standard recommendation)
• You've tried sermorelin and want more effect
• You're comfortable with a research-compound status

Choose Ipamorelin If:

• You're sensitive to hormonal changes
• You want to avoid any cortisol or appetite effects
• You prefer the most selective option
• You're combining it with CJC-1295 (strongly recommended)
• You have a history of adrenal or cortisol issues

Choose CJC-1295 + Ipamorelin If:

• You want maximum physiological GH optimization
• You've done the research and are comfortable with combination therapy
• You can afford the combined cost
• Your goals include significant body composition changes
• Your provider is experienced with peptide protocols

The Bottom Line

For most patients seeking growth hormone optimization in 2026, the CJC-1295/ipamorelin combination represents the best balance of efficacy, safety, and cost. It produces the most robust GH response while preserving natural pulsatility and feedback mechanisms.

Sermorelin remains an excellent entry point for patients cautious about peptide therapy, while ipamorelin monotherapy is ideal for those prioritizing tolerability over potency.

Regardless of which peptide you choose, the key principles remain the same: work with a knowledgeable provider, monitor your labs, and give the therapy adequate time (minimum 3–6 months) to produce meaningful results.

---

Disclaimer: This article is for educational purposes only and does not constitute medical advice. None of these peptides are FDA-approved for anti-aging, performance enhancement, or body composition optimization. Always consult a qualified healthcare provider before beginning any peptide therapy. Individual responses vary based on age, baseline GH status, genetics, and concurrent health conditions.